menu
    • menu
    [{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Jade Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Jade Biosciences \/ Fairmount","highestDevelopmentStatusID":"12","companyTruncated":"Jade Biosciences \/ Fairmount"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aerovate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"JADE-001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Jade Biosciences \/ Jade Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Jade Biosciences

    Menu

    Jade Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jade Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Recipient : Aerovate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement

                            Details : The combined company will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL monoclonal antibody for IgA nephropathy.

                            Brand Name : JADE-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 31, 2024

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Recipient : Aerovate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jade Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Jade Biosciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : Fairmount

                            Deal Size : $80.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Jade Biosciences Launches with $80M to Develop Therapies for Autoimmune Diseases

                            Details : The funding will be used to support Jade's plans to develop targeted therapies for indications with high unmet need across inflammation and immunology.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : Fairmount

                            Deal Size : $80.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth